Morgan Stanley initiates Cipla stock with Underweight rating on muted growth

Morgan Stanley has initiated coverage on Cipla (NS:CIPLA) with an Underweight rating and a price target of INR1,400.00, citing significant concerns over the company's earnings growth outlook. Despite Cipla's strong market position in Indian chronic therapies and diversified revenue streams, the firm projects a -2% EPS CAGR for fiscal years 2025-2027, attributing this to increasing competition and anticipated weakening gRevlimid sales due to patent cliffs, which are expected to compress EBITDA margins to 23.5-24.5% in FY26 from 26% in FY25.

Analysis

Morgan Stanley has initiated coverage on Cipla Ltd. with an Underweight rating and an INR 1,400 price target, signaling a cautious outlook on the company's profitability. The core of this thesis is a projection of muted earnings growth, with a forecasted -2% Earnings Per Share (EPS) Compound Annual Growth Rate (CAGR) for fiscal years 2025 through 2027. This negative outlook is driven by two primary headwinds: intensifying competition across Cipla's portfolio and the anticipated decline in gRevlimid sales due to its patent cliff, which is expected to materially impact margins starting in the second half of fiscal year 2026. This pressure is reflected in Cipla's own EBITDA margin guidance, which anticipates a contraction to 23.5-24.5% in FY26 from 26% in FY25. While Morgan Stanley acknowledges Cipla's fundamental strengths, including its number two ranking in India's chronic therapies market and a diversified revenue stream (42% India, 29% US), the near-term earnings challenges outweigh these positives. The firm's price target is derived from a 22.5x price-to-earnings multiple on its downbeat FY27 estimates.

Key Decisions for Investors

• Given the Underweight rating and projected negative EPS CAGR, investors should consider the significant risk of margin compression and re-evaluate long positions in Cipla.
• Monitor the sales performance of gRevlimid and competitive landscape developments closely, as these are the key catalysts for the bearish thesis materializing in the second half of fiscal year 2026.
• While the near-term outlook is negative, keep an eye on the execution of U.S. pipeline launches, including peptide products in FY26 and gSymbicort in FY27, as potential long-term catalysts that could counter the current headwinds.
• Use the INR 1,400 price target, based on a 22.5x FY27 P/E multiple, as a key valuation benchmark to assess the risk-reward profile at current market prices.